Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

Tongji University

Status: Unknown

Conditions: Obesity

Treatments: Drug: Exenatide

Study type: Interventional

Funder types: Other

Identifiers

NCT02118376

GLP-1

Details and patient eligibility

About

GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

Full description

As a treatment for type 2 diabetesGlucagon like peptide -1 (Glucan-like peptide-1, GLP-1) receptor agonists plays the role of promoting insulin secretion, inhibiting glucagon secretion，and also has the central and peripheral effects,it can inhibit appetite,reduce weight.GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

Enrollment: 20 estimated patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of overweight and type 2 diabetes mellitus

Exclusion criteria

• Poor body condition (severe liver and kidney dysfunction)
• Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach operation, malignant tumor, previous use of systemic corticosteroids (local or inhalation of exceptions) heart function or niacin, incomplete
• serious endocrine disease
• genetic disease

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

exenatide

Experimental group

Description:

exenatide, 5ug, bid, 3months

Treatment:

Drug: Exenatide